CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for BRIM Biotechnology Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

BRIM Biotechnology Inc
2F
No.36 Yuanqu Street, Nangang District
Phone: +886 226598586p:+886 226598586 TAIPEI, 114  Taiwan Ticker: 68856885
Business Summary
BRIM Biotechnology Inc is a Taiwan-based company mainly engaged in drug discovery and development. The Company's product line is based on the pigment epithelium-derived factor (PEDF) and its derived short-chain polypeptide technology platform for multiple therapeutic areas and indications. The Company has four product candidates, BRM421 Dry Eye, BRM423 Severe Corneal Injury, BRM424 Neurotrophic Keratitis and BRM521 Degenerative Arthritis. BRM421 is primarily indicated for the treatment and repair of dry eye disease (DES) with corneal damage.
(Source: N-30D)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023-----

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board QunLin 2/8/2023 2/8/2023
Vice Chairman of the Board, Chief Strategy Officer HaishanJian 3/1/2023
Chief Operating Officer Mei-HuiKuo 1/2/2024 2/17/2023
8 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 115,754,000 (As of 12/31/2023)
Stock Exchange: TPO
Fax Number: +886 226598779


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 26, 2024